112 related articles for article (PubMed ID: 18221369)
1. The separation of antagonist from agonist effects of trisubstituted purines on CaV2.2 (N-type) channels.
Buraei Z; Elmslie KS
J Neurochem; 2008 May; 105(4):1450-61. PubMed ID: 18221369
[TBL] [Abstract][Full Text] [Related]
2. Slowed N-type calcium channel (CaV2.2) deactivation by the cyclin-dependent kinase inhibitor roscovitine.
Buraei Z; Anghelescu M; Elmslie KS
Biophys J; 2005 Sep; 89(3):1681-91. PubMed ID: 15951378
[TBL] [Abstract][Full Text] [Related]
3. Roscovitine differentially affects CaV2 and Kv channels by binding to the open state.
Buraei Z; Schofield G; Elmslie KS
Neuropharmacology; 2007 Mar; 52(3):883-94. PubMed ID: 17125805
[TBL] [Abstract][Full Text] [Related]
4. Roscovitine binds to novel L-channel (CaV1.2) sites that separately affect activation and inactivation.
Yarotskyy V; Gao G; Du L; Ganapathi SB; Peterson BZ; Elmslie KS
J Biol Chem; 2010 Jan; 285(1):43-53. PubMed ID: 19887376
[TBL] [Abstract][Full Text] [Related]
5. Roscovitine inhibits CaV3.1 (T-type) channels by preferentially affecting closed-state inactivation.
Yarotskyy V; Elmslie KS
J Pharmacol Exp Ther; 2012 Feb; 340(2):463-72. PubMed ID: 22088954
[TBL] [Abstract][Full Text] [Related]
6. Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels.
Yarotskyy V; Elmslie KS
Br J Pharmacol; 2007 Oct; 152(3):386-95. PubMed ID: 17700718
[TBL] [Abstract][Full Text] [Related]
7. ZC88, a novel N-type calcium channel blocker from 4-amino-piperidine derivatives state-dependent inhibits Cav2.2 calcium channels.
Zhang S; Yang L; Zhang K; Liu X; Dai W; Zhang C; Yong Z; Li J; Zheng J
Brain Res; 2015 Apr; 1605():12-21. PubMed ID: 25681549
[TBL] [Abstract][Full Text] [Related]
8. Domain III regulates N-type (CaV2.2) calcium channel closing kinetics.
Yarotskyy V; Gao G; Peterson BZ; Elmslie KS
J Neurophysiol; 2012 Apr; 107(7):1942-51. PubMed ID: 22205645
[TBL] [Abstract][Full Text] [Related]
9. Interference between two modulators of N-type (CaV2.2) calcium channel gating demonstrates that omega-conotoxin GVIA disrupts open state gating.
Yarotskyy V; Elmslie KS
Biochim Biophys Acta; 2010 Sep; 1798(9):1821-8. PubMed ID: 20471360
[TBL] [Abstract][Full Text] [Related]
10. (R)-roscovitine prolongs the mean open time of unitary N-type calcium channel currents.
DeStefino NR; Pilato AA; Dittrich M; Cherry SV; Cho S; Stiles JR; Meriney SD
Neuroscience; 2010 May; 167(3):838-49. PubMed ID: 20188151
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of direct Cav2.2 channel block by the κ-opioid receptor agonist U50488H.
Berecki G; Motin L; Adams DJ
Neuropharmacology; 2016 Oct; 109():49-58. PubMed ID: 27245500
[TBL] [Abstract][Full Text] [Related]
12. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.
Bettayeb K; Sallam H; Ferandin Y; Popowycz F; Fournet G; Hassan M; Echalier A; Bernard P; Endicott J; Joseph B; Meijer L
Mol Cancer Ther; 2008 Sep; 7(9):2713-24. PubMed ID: 18790752
[TBL] [Abstract][Full Text] [Related]
13. Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons.
Yan Z; Chi P; Bibb JA; Ryan TA; Greengard P
J Physiol; 2002 May; 540(Pt 3):761-70. PubMed ID: 11986366
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the triazine, T4, a representative from a novel series of CaV2 inhibitors with strong state-dependence, poor use-dependence, and distinctively fast kinetics.
Swensen AM; Niforatos W; Lee CH; Jarvis MF; McGaraughty S
Eur J Pharmacol; 2014 Dec; 745():234-42. PubMed ID: 25446431
[TBL] [Abstract][Full Text] [Related]
15. Voltage control of Ca²⁺ permeation through N-type calcium (Ca(V)2.2) channels.
Buraei Z; Liang H; Elmslie KS
J Gen Physiol; 2014 Sep; 144(3):207-20. PubMed ID: 25114024
[TBL] [Abstract][Full Text] [Related]
16. Open-state occupancy prevents gating charge relaxation of N-type (CaV2.2) calcium channels.
Yarotskyy V; Elmslie KS
Biophys J; 2009 Nov; 97(9):2446-55. PubMed ID: 19883587
[TBL] [Abstract][Full Text] [Related]
17. The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction.
Cho S; Meriney SD
Eur J Neurosci; 2006 Jun; 23(12):3200-8. PubMed ID: 16820010
[TBL] [Abstract][Full Text] [Related]
18. Novel mechanism of voltage-gated N-type (Cav2.2) calcium channel inhibition revealed through α-conotoxin Vc1.1 activation of the GABA(B) receptor.
Huynh TG; Cuny H; Slesinger PA; Adams DJ
Mol Pharmacol; 2015 Feb; 87(2):240-50. PubMed ID: 25425625
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of olomoucine II.
Krystof V; Lenobel R; Havlícek L; Kuzma M; Strnad M
Bioorg Med Chem Lett; 2002 Nov; 12(22):3283-6. PubMed ID: 12392733
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
